Cronos Group Stock Forecast, Price & News

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cronos Group in the last year. There are currently 2 sell ratings, 4 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Cronos Group stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CRON, but not buy additional shares or sell existing shares.
View analyst ratings for Cronos Group or view top-rated stocks.

8 Wall Street research analysts have issued 12-month price targets for Cronos Group's shares. Their CRON stock forecasts range from $3.00 to $6.00. On average, they anticipate Cronos Group's share price to reach $4.37 in the next twelve months. This suggests a possible upside of 40.6% from the stock's current price.
View analysts' price targets for Cronos Group or view top-rated stocks among Wall Street analysts.

Cronos Group's stock was trading at $3.92 at the beginning of the year. Since then, CRON stock has decreased by 20.7% and is now trading at $3.11.
View the best growth stocks for 2022 here.

Cronos Group is scheduled to release its next quarterly earnings announcement on Friday, August 5th 2022.
View our earnings forecast for Cronos Group.

Cronos Group Inc. (NASDAQ:CRON) issued its earnings results on Tuesday, May, 10th. The company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.08) by $0.01. The firm had revenue of $25.03 million for the quarter, compared to analysts' expectations of $30.66 million. Cronos Group had a negative trailing twelve-month return on equity of 15.92% and a negative net margin of 36.04%. Cronos Group's revenue was up 98.5% on a year-over-year basis. During the same period in the prior year, the company posted ($0.12) EPS.
View Cronos Group's earnings history.

Some companies that are related to Cronos Group include Tilray (TLRY), Canopy Growth (CGC), USANA Health Sciences (USNA), Cresco Labs (CRLBF), Sundial Growers (SNDL), True Drinks (TRUU), Canopy Rivers (RIV), Bright Green (BGXX), Ascend Wellness (AAWH), Ayr Wellness (AYRWF), Haymaker Acquisition Corp. III (HYAC), Aurora Cannabis (ACB), Mind Medicine (MindMed) (MNMD), Exactus (EXDI) and MariMed (MRMD).
View all of CRON's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Cronos Group investors own include (CGC), Aurora Cannabis (ACB), Tilray (TLRY), (APHA), NVIDIA (NVDA), Advanced Micro Devices (AMD), Dollar Tree (DLTR), Micron Technology (MU), Alibaba Group (BABA) and OrganiGram (OGI).

Cronos Group trades on the NASDAQ under the ticker symbol "CRON."

Cronos Group's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (1.67%), Mirae Asset Global Investments Co. Ltd. (0.50%), Mirae Asset Global Investments Co. Ltd. (0.50%), Connor Clark & Lunn Investment Management Ltd. (0.33%), Dimensional Fund Advisors LP (0.24%) and TD Asset Management Inc. (0.15%). Company insiders that own Cronos Group stock include Jason Marc Adler, Michael Ryan Gorenstein and Todd Kevin Abraham.
View institutional ownership trends for Cronos Group.

CRON stock was sold by a variety of institutional investors in the last quarter, including Mirae Asset Global Investments Co. Ltd., Mirae Asset Global Investments Co. Ltd., Dimensional Fund Advisors LP, BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp, IMC Chicago LLC, Janney Montgomery Scott LLC, Group One Trading L.P., and Commonwealth Equity Services LLC. Company insiders that have sold Cronos Group company stock in the last two years include Jason Marc Adler, and Michael Ryan Gorenstein.
View insider buying and selling activity for Cronos Group or view top insider-selling stocks.

CRON stock was purchased by a variety of institutional investors in the last quarter, including Simplex Trading LLC, Vanguard Group Inc., Winning Points Advisors LLC, Connor Clark & Lunn Investment Management Ltd., Cibc World Market Inc., Jane Street Group LLC, Walleye Trading LLC, and Cutler Group LP.
View insider buying and selling activity for Cronos Group or or view top insider-buying stocks.

Shares of CRON can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CRON stock can currently be purchased for approximately $3.11.

Cronos Group (NASDAQ:CRON) has a market capitalization of $1.17 billion and generates $74.43 million in revenue each year. The company earns $-396.11 million in net income (profit) each year or ($0.090010) on an earnings per share basis.

Cronos Group employs 626 workers across the globe.

Cronos Group's mailing address is 111 PETER STREET SUITE 300, TORONTO A6, M5V 2G9. The official website for Cronos Group is www.thecronosgroup.com. The company can be reached via phone at (416) 504-0004.